Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
April 02, 2018 10:20 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 02, 2018 (GLOBE NEWSWIRE) --
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that...
Madrigal Pharmaceuticals Reports 2017 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Clinical Update on MGL-3196
March 13, 2018 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
- MGL-3196 is a first-in-class, oral, once-daily, liver-directed, thyroid hormone receptor (THR) β -selective agonist that is being developed for patients with non-alcoholic steatohepatitis (NASH) and...
UPDATE -- Immuron Commences US Non-Deal Institutional Investor Roadshow
March 13, 2018 02:15 ET
|
Immuron Limited
MELBOURNE, Australia, March 13, 2018 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC)(NASDQ:IMRN) is pleased to release to shareholders and investors its...
Immuron Commences US Non-Deal Institutional Investor Roadshow
March 12, 2018 08:17 ET
|
Immuron Limited
MELBOURNE, Australia, March 12, 2018 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC)(NASDQ:IMRN) is pleased to release to shareholders and investors its...
Galectin Therapeutics to Present at 2nd Annual H.C. Wainwright NASH Investor Conference
March 08, 2018 08:30 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 08, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold...
Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Heterozygous Familial Hypercholesterolemia (HeFH)
February 08, 2018 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
-- Statistically significant improvement achieved in the reduction of LDL cholesterol (LDL-C) with MGL-3196 compared to placebo, the primary endpoint of this 12-week Phase 2 clinical trial in HeFH...
Madrigal Announces Acceptance of MGL-3196 Abstract for a Main Plenary Presentation at The International Liver Congress™ 2018
January 30, 2018 07:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL) today announced that Week 12 Phase 2 results for MGL-3196, its first-in-class, oral, once-daily,...
Galectin Therapeutics Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy Clinical Development Programs
January 25, 2018 08:30 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat non-alcoholic steatohepatitis...
Immuron to Receive $2.16M R&D Tax Concession Refund
January 24, 2018 09:30 ET
|
Immuron Limited
Melbourne, Australia, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) is pleased to announce that under the Australian Government’s Research and Development...
Madrigal Pharmaceuticals Prices Public Offering of Common Stock
December 18, 2017 23:26 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of...